| Long-term serotonin administration induces heart valve disease in rats BI Gustafsson, K Tømmerås, I Nordrum, JP Loennechen, A Brunsvik, ... Circulation 111 (12), 1517-1522, 2005 | 293 | 2005 |
| Rebound acid hypersecretion after long‐term inhibition of gastric acid secretion R Fossmark, G Johnsen, E Johanessen, HL Waldum Alimentary pharmacology & therapeutics 21 (2), 149-154, 2005 | 150 | 2005 |
| Gastric carcinoids after long‐term use of a proton pump inhibitor CS Jianu, R Fossmark, T Viset, G Qvigstad, Ø Sørdal, R Mårvik, ... Alimentary pharmacology & therapeutics 36 (7), 644-649, 2012 | 147 | 2012 |
| Adverse effects of proton pump inhibitors—evidence and plausibility R Fossmark, TC Martinsen, HL Waldum International journal of molecular sciences 20 (20), 5203, 2019 | 141 | 2019 |
| Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A R Fossmark, Ø Sørdal, CS Jianu, G Qvigstad, IS Nordrum, M Boyce, ... Alimentary pharmacology & therapeutics 36 (11-12), 1067-1075, 2012 | 123 | 2012 |
| Types of gastric carcinomas HL Waldum, R Fossmark International journal of molecular sciences 19 (12), 4109, 2018 | 120 | 2018 |
| Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint HL Waldum, G Qvigstad, R Fossmark, PM Kleveland, AK Sandvik Scandinavian journal of gastroenterology 45 (4), 389-394, 2010 | 101 | 2010 |
| Randomized clinical trial of topical tranexamic acid after reduction mammoplasty K Ausen, R Fossmark, O Spigset, H Pleym Journal of British Surgery 102 (11), 1348-1353, 2015 | 98 | 2015 |
| Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor CS Jianu, OJ Lange, T Viset, G Qvigstad, TC Martinsen, R Fougner, ... Scandinavian journal of gastroenterology 47 (1), 64-67, 2012 | 98 | 2012 |
| The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in … AK Stunes, I Westbroek, BI Gustafsson, R Fossmark, JH Waarsing, ... BMC endocrine disorders 11, 1-13, 2011 | 97 | 2011 |
| The regulation of gastric acid secretion–clinical perspectives HL Waldum, Ø Hauso, R Fossmark Acta Physiologica 210 (2), 239-256, 2014 | 96 | 2014 |
| Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition R Fossmark, CS Jianu, TC Martinsen, G Qvigstad, U Syversen, ... Scandinavian journal of gastroenterology 43 (1), 20-24, 2008 | 96 | 2008 |
| Gastritis, gastric polyps and gastric cancer H Waldum, R Fossmark International journal of molecular sciences 22 (12), 6548, 2021 | 92 | 2021 |
| Antiulcer drugs and gastric cancer HL Waldum, B Gustafsson, R Fossmark, G Qvigstad Digestive diseases and sciences 50, S39-S44, 2005 | 87 | 2005 |
| Signet ring cells in gastric carcinomas are derived from neuroendocrine cells K Bakkelund, R Fossmark, I Nordrum, H Waldum Journal of Histochemistry & Cytochemistry 54 (6), 615-621, 2006 | 85 | 2006 |
| The phylogeny and biological function of gastric juice—microbiological consequences of removing gastric acid TC Martinsen, R Fossmark, HL Waldum International journal of molecular sciences 20 (23), 6031, 2019 | 74 | 2019 |
| Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis M Boyce, AR Moore, L Sagatun, BN Parsons, A Varro, F Campbell, ... British journal of clinical pharmacology 83 (3), 466-475, 2017 | 74 | 2017 |
| Proton pump inhibitors (PPIs) may cause gastric cancer–clinical consequences HL Waldum, Ø Sørdal, R Fossmark Scandinavian journal of gastroenterology 53 (6), 639-642, 2018 | 62 | 2018 |
| Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist TC Martinsen, S Kawase, R Håkanson, SH Torp, R Fossmark, G Qvigstad, ... Carcinogenesis 24 (12), 1887-1896, 2003 | 61 | 2003 |
| Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids CS Jianu, R Fossmark, U Syversen, Ø Hauso, V Fykse, HL Waldum Scandinavian journal of gastroenterology 46 (4), 456-463, 2011 | 59 | 2011 |
